摘要
目的比较阿立哌唑与利培酮治疗精神分裂症的疗效及安全性。方法将82例精神分裂症患者随机均分为两组,分别使用阿立哌唑和利培酮治疗,疗程8周,采用阳性与阴性症状量表(PANSS)评定疗效,采用副反应量表(TESS)评定不良反应。结果两组间疗效比较差异无显著性(P>0.05),阿立哌唑组不良反应较利培酮组少,但无明显差异(P>0.05)。结论阿立哌唑是一种安全有效、耐受性好的抗精神病药,值得临床推广。
Objective To compare the efficacy and safety of aripiprazole and risperidone in the treatment of episode schizophrenia. Methods 82 cases of episode schizophrenia were equally divided into two groups and treated with aripiprazole and risperidone respectively. The curative efficacy and the adverse effects were evaluated by PANSS and TESS respectively. Results Both medicines had comparable efficacy. The incidence of adverse effects in the aripiprazole group was lower than that in the risperidone group without significant difference. Conclusion Aripiprazole is as effective as risperidone for treating episode schizophrenia with lower adverse effects.
出处
《中国药业》
CAS
2009年第3期53-54,共2页
China Pharmaceuticals
